Why Infusion Is Becoming the Next Battleground for Self-Insured Employer Direct Contracting

The next major direct-contracting opportunity may not begin with a hospital negotiation.

It may begin 60 to 90 days before the claim exists.

World Class Health announced two related expansions this week that point toward a broader change in self-insured employer healthcare strategy.

On September 2, the company introduced an AI Specialty Clinic designed to identify members likely to need specialty care months before a claim is filed, engage them, and route them toward selected providers with disclosed prices.

A day later, World Class Health launched specialty infusion services covering more than 270 infusions representing 95% of commercial specialty-infusion spend, according to the company. It says moving appropriate cases away from hospital outpatient settings produces average savings of roughly 46% against commercial hospital outpatient benchmarks.

The more important story is not one vendor's product launch.

It is the evolution of direct contracting from price negotiation after demand appears to demand identification, navigation, and contracted care before the expensive claim occurs.

Why infusion is structurally attractive

Specialty infusion combines several characteristics that make it unusually relevant for self-insured employers.

The claims are expensive

A relatively small number of members can generate material specialty-drug and facility spend. That makes individual cases worth identifying and managing rather than treating them as background network utilization.

Site of care can materially change the price

The drug may be the same, but the location in which it is administered can change the economics substantially.

Hospital outpatient departments frequently carry very different pricing and facility economics from physician offices, ambulatory infusion centers, or clinically appropriate home infusion.

That makes infusion a purchasing problem as well as a clinical problem.

The care is often predictable

Many infusion therapies involve recurring treatment schedules. Once a member is identified and clinically appropriate alternatives are established, the plan has an opportunity to influence where subsequent treatments occur.

That makes steerage more realistic than in truly emergent care.

The direct-contracting lesson: intervene before the referral hardens

Employers often discover high-cost specialty utilization too late.

By the time a claim appears, the member may already have a specialist, authorization, scheduled procedure, infusion site, and established treatment pathway. Changing direction at that point is harder operationally and can create a poor member experience.

The AI Specialty Clinic concept is notable because it attempts to move the intervention point earlier.

World Class Health says its model identifies likely specialty-care needs 60 to 90 days before a claim is filed, with licensed nurses engaging members while AI supports intake, scheduling and follow-up.

Whether this specific model delivers at scale remains to be seen. But strategically, the direction makes sense.

The earlier a plan can identify addressable demand, the more useful a direct contract becomes.

A negotiated rate has limited value if the member never reaches the contracted provider.

This changes what a specialty-care platform is selling

The first generation of centers of excellence largely sold a curated provider network and a negotiated bundle.

The next generation increasingly needs four capabilities at once:

1. Prediction — identify members likely to need expensive care.
2. Clinical validation — confirm that the proposed care and site are appropriate.
3. Navigation — engage the member early enough to influence the pathway.
4. Contracting — route the member into a provider relationship with transparent, pre-negotiated economics.

That combination is much more powerful than a discounted network alone.

It also creates a higher bar for employers evaluating vendors. The relevant question becomes not simply, "What discount do you have?" but "How many eligible cases do you actually identify and redirect before they hit the incumbent channel?"

Why infusion could be a template for other categories

Infusion is only one example of care where timing plus site-of-care economics matter.

The same framework can apply to:

• elective orthopedic surgery;
• spine procedures;
• advanced imaging;
• certain cardiac procedures;
• bariatric surgery;
• oncology pathways;
• other high-cost specialty care where the employer has time to intervene.

The economic opportunity is greatest when the plan can identify a likely future event, compare provider and site options, validate clinical appropriateness, and create a low-friction member path into a contracted channel.

That is direct contracting as an operating system rather than a contract file.

Employers should demand auditable savings

World Class Health says its infusion program measures savings against the member's own prior treatment cost when a historical claim is available and otherwise against a published outpatient benchmark for the member's market.

That kind of methodology is important because specialty-care savings claims can become difficult to validate when the comparison point is vague.

Employers evaluating infusion or other specialty carve-outs should ask vendors to define:

• the baseline price used for each case;
• whether savings are gross or net of vendor fees;
• how cases without historical claims are benchmarked;
• how drug acquisition cost and facility fees are treated;
• what happens when the recommended site is not clinically appropriate;
• how many eligible members are identified, contacted, engaged, and successfully redirected;
• how savings interact with stop-loss coverage;
• whether quality and outcomes are measured alongside price.

The best specialty-care contract is not the one with the largest theoretical discount. It is the one that produces measurable savings on cases that actually move.

The TPA and plan-design implications

Early identification and navigation do not work in isolation.

The employer's TPA still has to recognize the contracted arrangement, route claims correctly, apply member cost sharing as intended, maintain eligibility data, and support the plan design.

Member incentives also matter. If a plan identifies a lower-cost infusion option but creates higher friction or no meaningful member benefit, steerage may remain weak.

Employers should therefore treat specialty direct contracting as an integrated design exercise involving the vendor, TPA, stop-loss carrier, benefits advisor, and member communication strategy.

The bigger market shift

Direct contracting was originally framed as a negotiation strategy: remove the carrier intermediary and contract directly with a provider.

That remains part of the model.

But the more sophisticated opportunity is emerging upstream.

Find the future claim. Validate the care. Engage the member. Route the case. Then apply the direct contract.

Infusion is particularly well suited to that model because the costs are high, treatment is often scheduled, and site-of-care differences can be significant.

If that operating model proves repeatable, direct contracting will increasingly compete not just with carrier network rates, but with the carrier's ability to control the entire care pathway.

That is a much larger opportunity.

Sources: World Class Health, "The AI Specialty Clinic," September 2, 2026; World Class Health, "Infusion Care," September 3, 2026, both distributed through PR Newswire.